Tiziana Life Sciences (TLSA) Stock Overview
A biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TLSA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Tiziana Life Sciences Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$2.60 |
| 52 Week Low | US$0.63 |
| Beta | 0.20 |
| 1 Month Change | 7.73% |
| 3 Month Change | 29.14% |
| 1 Year Change | 107.73% |
| 3 Year Change | 159.65% |
| 5 Year Change | n/a |
| Change since IPO | 30.00% |
Recent News & Updates
Recent updates
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting
Jun 14Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis
Dec 24Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Sep 19
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate
Jun 03Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?
Jan 16Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy
Oct 12Tiziana chief medical officer further increases holdings in company
Sep 23Tiziana Life Sciences executive chairman further raises stake in company
Sep 16Tiziana executive chairman raises stake in company again, buys more shares
Aug 25Tiziana Life Sciences discloses share purchase by executive chairman
Aug 17Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?
Aug 15Tiziana Life Sciences CEO Kunwar Shailubhai resigns
Jul 15Shareholder Returns
| TLSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 3.1% | 0.8% |
| 1Y | 107.7% | -1.6% | 18.1% |
Return vs Industry: TLSA exceeded the US Biotechs industry which returned -4.3% over the past year.
Return vs Market: TLSA exceeded the US Market which returned 18% over the past year.
Price Volatility
| TLSA volatility | |
|---|---|
| TLSA Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLSA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLSA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9 | Ivor Elrifi | www.tizianalifesciences.com |
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications.
Tiziana Life Sciences Ltd Fundamentals Summary
| TLSA fundamental statistics | |
|---|---|
| Market cap | US$240.76m |
| Earnings (TTM) | -US$11.86m |
| Revenue (TTM) | n/a |
Is TLSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.86m |
| Earnings | -US$11.86m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TLSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/01 14:27 |
| End of Day Share Price | 2025/10/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tiziana Life Sciences Ltd is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Elemer Piros | Lucid Capital Markets |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |